Current status of targeted therapies for mantle cell lymphoma

Drugs

Volumn 71, Issue 17, 2011, Pages 2307-2326

  Chang, Julie E ^a   Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Aganirsen; Alvocidib; Bendamustine; Bortezomib; Carfilzomib; Cladribine; Delanzomib; Everolimus; Fostamatinib; Ibritumomab tiuxetan Y 90; Iodine 131 tositumomab; Lenalidomide; Mantle cell lymphoma; Marizomib; MLN 9708; Navitoclax; Non Hodgkins lymphoma; Obatoclax; Obinutuzumab; Ofatumumab; Panobinostat; PCI 32765; Ridaforolimus; Rituximab; Temsirolimus; Thalidomide; Vorinostat

Indexed keywords

AGANIRSEN; B LYMPHOCYTE RECEPTOR; BORTEZOMIB; CAL 101; CYCLIN DEPENDENT KINASE INHIBITOR; EVEROLIMUS; FLAVOPIRIDOL; FOSTAMATINIB; GS 1101; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NAVITOCLAX; OBATOCLAX; OBINUTUZUMAB; OFATUMUMAB; PANOBINOSTAT; PCI 32765; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN BCL 2 INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RIDAFOROLIMUS; RITUXIMAB; RO 5072759; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER FATIGUE; CANCER RELAPSE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FOLLICULAR LYMPHOMA; GAIT DISORDER; HODGKIN DISEASE; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MOOD CHANGE; MOUTH DISEASE; MOUTH SORE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; T CELL LYMPHOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY;

MAMMALIA;

EID: 81155123619     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11594630-000000000-00000     Document Type: Review

References (131)

1. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114 (8): 1469-76
2. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27 (8): 1209-13
3. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82 (3): 567-75 (Pubitemid 28112997)
4. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27 (4): 511-8
5. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20 (5): 1288-94 (Pubitemid 34177435)
6. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma StudyGroup (GLSG). JClinOncol 2005; 23 (9): 1984-92 (Pubitemid 46211378)
7. Hoster E, UnterhaltM, Wormann B, et al. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial [abstract no. 3049]. Blood 2008; 112 (11): 1048
8. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16 (8): 2780-95 (Pubitemid 28363044)
9. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89 (11): 3909-18
10. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic LymphomaGroup. Blood 2008; 112 (7): 2687-93
11. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27 (36): 6101-8
12. Delarue R, Haioun C, Ribrag V, et al. RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA [abstract no. 581]. Blood 2008; 112 (11): 218
13. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23 (28): 7013-23
14. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantlecell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105 (7): 2677-84 (Pubitemid 40450320)
15. Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008; 19 (7): 1327-30 (Pubitemid 351911966)
16. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26 (27): 4473-9
17. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23 (15): 3383-9
18. Weide R, Pandorf A, Heymanns J, et al. Bendamustine/Mitoxantrone/ Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004; 45 (12): 2445-9 (Pubitemid 40081187)
19. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract no. 405]. Blood 2009; 114 (22): 168-9
20. Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008; 113 (1): 108-16 (Pubitemid 351980749)
21. Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42 (5): 1015-22 (Pubitemid 32827523)
22. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17 (2): 546-53 (Pubitemid 29075241)
23. Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107 (7): 1542-50 (Pubitemid 44546915)
24. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27 (23): 3822-9
25. Ansell SM, Inwards DJ, Rowland Jr KM, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113 (3): 508-14
26. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23 (26): 6409-14 (Pubitemid 46222241)
27. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12 (17): 5165-73 (Pubitemid 44453345)
28. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14 (9): 2756-62
29. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with relapsed or refractory non-Hodgkin lymphoma [abstract no. 1777]. Blood 2010; 116 (21): 741
30. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-Cell malignancies: results from a phase I study [abstract no. 964]. Blood 2010; 116 (21): 425
31. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115 (13): 2578-85
32. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21 (9): 1740-5 (Pubitemid 46638586)
33. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145 (3): 344-9
34. Czuczman MS, Reeder CB, Polikoff J, et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma [abstract no. 8509]. J Clin Oncol 2008; 26 (15s): 456s
35. Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010; 101 (1): 196-200
36. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27 (31): 5213-8
37. Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma [abstract no. 935]. Blood 2009; 114 (22): 385-6
38. Coiffier B, Bosly A, Wu KL, et al. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter phase II study [abstract no. 3955]. Blood 2010; 116 (21): 1613
39. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111 (12): 5486-95
40. Salles G, Morschhauser F, Lamy T, et al. Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin Lymphoma (NHL) [abstract no. 1704]. Blood 2009; 114 (22): 679
41. Sehn LH, Assouline SE, Stewart DA, et al. A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed/refractory CD20+ malignant disease [abstract no. 934]. Blood 2009; 114 (22): 385
42. Salles A, Morschhauser F, Thieblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated patients: first results from a phase II study in patients with relapsed/refractory indolent NHL (INHL) [abstract no. 0558]. Haematologica 2010; 95 Suppl. 2: 221
43. Goy A, Ford P, Feldman T, et al. A phase I trial of the pan bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma [abstract no. 2569]. Blood 2007; 110 (11): 757a
44. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11 (12): 1149-59
45. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24 (30): 4867-74 (Pubitemid 46655613)
46. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13 (18 Pt 1): 5291-4 (Pubitemid 47510352)
47. Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib, and rituximab in patients (pts) with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial [abstract no. 924]. Blood 2009; 114 (22): 381
48. Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. Epub 2011 Aug 16
49. Morrison VA, Johnson JL, Jung S, et al. A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): results of a planned interim analysis [abstract no. 8106]. J Clin Oncol 2010; 28 (15s): 599s
50. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23 (3): 630-9 (Pubitemid 46224241)
51. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9 (17): 6316-25 (Pubitemid 38031815)
52. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4 (5): 349-60 (Pubitemid 38579481)
53. Perez-Galan P, Roue G, Villamor N, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107 (1): 257-64 (Pubitemid 43053550)
54. Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171 (1): 88-95 (Pubitemid 36745276)
55. Fu L, Lin-Lee YC, Pham LV, et al. Constitutive NFkappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006; 107 (11): 4540-8 (Pubitemid 43801383)
56. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20 (3): 520-5
57. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18 (1): 116-21 (Pubitemid 46152510)
58. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12 (5): 431-40
59. Goy A, Bernstein SH, McDonald A, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010; 51 (7): 1269-77
60. Dick LR, Fleming PE. Building on bortezomib: secondgeneration proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15 (5-6): 243-9
61. Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006; 7 (4): 285-94 (Pubitemid 44043658)
62. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6 (3): 184-92 (Pubitemid 43292562)
63. LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Drug Resist Updat 2008; 11 (1-2): 32-50
64. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010; 2010: 265-70
65. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4 (5): 335-48 (Pubitemid 38579480)
66. Briones J. Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2009; 9 (9): 1305-16
67. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356 (22): 2271-81 (Pubitemid 46849157)
68. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372 (9637): 449-56
69. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23 (23): 5347-56 (Pubitemid 46206988)
70. Reeder C, Gornet M, Habermann T, et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed, agressive non-Hodgkin lymphoma [abstract no. 121]. Blood 2007; 110 (11): 44a
71. Zhou Y, Jin L, Pittaluga S, et al. PI3K a selective inhibitor induces growth inhibition in mantle cell lymphoma [abstract no. 1812]. Blood 2010; 116 (21): 757
72. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117 (2): 591-4
73. Flinn IW, Schreeder MT, Wagner-Johnston N, et al. A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110d, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies [abstract no. 2832]. Blood 2010; 116 (21): 1168
74. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006; 176 (10): 5715-9
75. Pogue SL, Kurosaki T, Bolen J, et al. B cell antigen receptorinduced activation of Akt promotes B cell survival and is dependent on Syk kinase. J Immunol 2000; 165 (3): 1300-6 (Pubitemid 30604558)
76. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111 (4): 2230-7 (Pubitemid 351451430)
77. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010; 28 (3): 418-23
78. Kitada S, Zapata JM, Andreeff M, et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96 (2): 393-7 (Pubitemid 30463354)
79. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92 (10): 3804-16 (Pubitemid 28525207)
80. Tay K, Shapiro G, Disinski M, et al. Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) [abstract no. 8563]. J Clin Oncol 2009; 27 (15s): 449s
81. Ruan J, Coleman M, Leonard JP. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park) 2009; 23 (8): 683-90
82. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4 (4): 314-22 (Pubitemid 38525287)
83. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104 (8): 2269-71 (Pubitemid 39331822)
84. Harel S, Bachy E, Haioun C, et al. Efficacy and safety of thalidomide in mantle cell lymphoma: results of the French ATU Program [abstract no. 1794]. Blood 2010; 116 (21): 749
85. Dredge K, Marriott JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002; 22 (5-6): 425-37 (Pubitemid 36548952)
86. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87 (10): 1166-72 (Pubitemid 35418112)
87. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26 (30): 4952-7
88. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in patients with relapsed refractory mantle cell lymphoma: clinical results and modifications of angiogenic biomarkers [abstract no. 966]. Blood 2010; 116 (21): 425-6s
89. Wang M, Fayad L, Hagemeister F, et al. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy [abstract no. 8030]. J Clin Oncol 2007; 25 (18S): 448s
90. Ahmadi T, Chong EA, Gordon A, et al. Phase II trial of lenalidomide-dexamethasone-rituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab [abstract no. 3962]. Blood 2010; 116 (21): 1616
91. Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110 (7): 2667-73 (Pubitemid 47523191)
92. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002; 11 (12): 1695-713 (Pubitemid 35469917)
93. Leshchenko VV, Kuo PY, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116 (7): 1025-34
94. Heider U, Kaiser M, Sterz J, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006; 76 (1): 42-50
95. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109 (1): 31-9 (Pubitemid 46053039)
96. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25 (21): 3109-15 (Pubitemid 47218059)
97. Kirschbaumm M, Popplewellm L, Delioukinam ML, et al. A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) plus rituximab in newly diagnosed, relapsed or refractory indolent non-Hodgkin's lymphoma [abstract no. 3957]. Blood 2010; 116 (21): 1614
98. Kirschbaum M, Popplewell L, Nademanee A, et al. A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin's lymphoma. A California Cancer Consortium study [abstract no. 1564]. Blood 2008; 112 (11): 554-5
99. Rao R, Fiskus W, Yang Y, et al. Co-treatment with panobinostat enhances bortezomib-induced unfolded protein response, endoplasmic reticulum stress and apoptosis of human mantle cell lymphoma cells [abstract no. 887]. Blood 2008; 112 (11): 327
100. Hernandez-Ilizaliturri FJ, Mavis C, Maraj I, et al. Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the anti-tumor activity of bortezomib (BTZ) in rituximab-chemotherapy sensitive and resistant lymphoma cell lines [abstract no. 3936]. Blood 2010; 116 (21): 1605s
101. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27 (10): 1607-14
102. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377 (9759): 42-51
103. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108 (13): 4003-8 (Pubitemid 44920177)
104. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108 (10): 3295-301 (Pubitemid 44794222)
105. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28 (17): 2853-8
106. Taverna CJ, Bassi S, Hitz F, et al. First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03 [abstract no. 8534]. J Clin Oncol 2009; 27 (15s): 442s
107. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6 (3): 257-62
108. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of singleagent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23 (4): 705-11 (Pubitemid 46224169)
109. Kluin-Nelemans JC, Hoster E, Hermine O, et al. R-CHOP versus R-FC followed by maintenance with rituximab or IFN: first results of a randomized trial for elderly patients with mantle cell lymphoma [abstract no. 016]. Ann Oncol 2011; 22 Suppl. 4: 86
110. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101 (2): 391-8 (Pubitemid 36082841)
111. Weigert O, von Schilling C, Rummel MJ, et al. Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory mantle cell lymphoma (MCL) after/not appropriate for autologous stem cell transplantation (ASCT): a phase II trial of the European MCL network [abstract no. 4786]. Blood 2005; 106 (11): 277b
112. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin-) in patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract no. 2714]. Blood 2006; 108 (11): 767a
113. Morschhauser F, Dreyling M, Rohatiner A, et al. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009; 14 Suppl. 2: 17-29
114. Zelenetz AD, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract no. 7560]. J Clin Oncol 2006; 24 (18s): 436a
115. Smith MR, Zhang L, Gordon LI, et al. Phase II study of R-CHOP followed by 90Y-Ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499 [abstract no. 389]. Blood 2007; 110 (11): 121a
116. Jurczak W, Giza A, Krochmalczyk D, et al. Radioimmunotherapy (RIT) as an alternative consolidation of MCL patients not eligible for transplant protocols: final analysis of multicenter Polish Lymphoma Research Group (PLRG) trial with 90Y-Zevalin (90Y-ibritumomab tiuxetan) [abstract no. 303]. Ann Oncol 2008; 19 Suppl. 4: iv173
117. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177 (1): 362-71 (Pubitemid 43939148)
118. Li B, Zhao L, Guo H, et al. Characterization of a rituximab variant with potent antitumor activity against rituximabresistant B-cell lymphoma. Blood 2009; 114 (24): 5007-15
119. Du J, Yang H, Guo Y, et al. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009; 46 (11-12): 2419-23
120. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010; 28 (21): 3525-30
121. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111 (3): 1094-100 (Pubitemid 351213387)
122. Wierda WG, Kipps T, Mayer J, et al. Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine-and alemtuzumabrefractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL) [abstract no. 7044]. J Clin Oncol 2009; 27 (15s): 366s
123. Dalle S, Reslan L, Manquat SB, et al. Compared antitumor activity of GA101 and rituximab against the human RL follicular lymphoma xenografts in SCID beige mice [abstract no. 1585]. Blood 2008; 112 (11): 562
124. Herter S, Waldhauer I, Otz T, et al. Superior efficacy of the novel type II, glycoengineered CD20 antibody GA101 vs. the type I CD20 antibodies rituximab and ofatumumab [abstract no. 3925]. Blood 2010; 116 (21): 1601
125. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010; 16 (16): 4094-104
126. Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68 (9): 3413-20
127. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15 (4): 1126-32
128. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104 (49): 19512-7
129. Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109 (10): 4441-9 (Pubitemid 46743414)
130. Perez-Galan P, Roue G, Lopez-Guerra M, et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008; 22 (9): 1712-20
131. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2011; 80 (11): 69-86